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with a routinely used method (Jaffé colorimetric assay) 
proved high agreement (R 2 = 0.9102).  Conclusions: The new 
method is a valuable addition to the toolbox of LC-MS/MS 
laboratories where excretion of urinary compounds is stud-
ied. The ‘dilute and shoot’ approach to isotope dilution tan-
dem mass spectrometry makes the new method highly ac-
curate as well as cost- and time-efficient. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) is gaining importance as a convenient and 
flexible tool for quantitative determination of a wide 
range of drugs, toxins and endogenous molecules from 
urinary samples. To account for variations of urine dilu-
tion in spot urine samples, calculation of the creatinine 
ratio is often performed  [1, 2] . The method presented here 
is intended to be useful when additional determination of 
urinary creatinine is desirable along with LC-MS/MS as-
says of substances excreted in urine, e.g. to report drug or 
drug metabolite concentrations in urine  [3] , to evaluate 
specific markers of oxidative stress in biological studies 
 [4] or to detect lung cancer risk from exposure to cigarette 
smoke  [5] .
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 Abstract 
 Background/Aims: Excretion of urinary compounds in spot 
urine is often estimated relative to creatinine. For the grow-
ing number of liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) assays of urine-excreted molecules, a 
fast and accurate method for determination of creatinine is 
needed.  Methods: A high-throughput flow injection tan-
dem mass spectrometry method for exact quantitation of 
creatinine in urine has been developed and validated. Sam-
ple preparation used only two-step dilution for protein pre-
cipitation and matrix dilution. Flow injection analysis with-
out chromatographic separation allowed for total run times 
of 1 min per sample. Creatinine concentrations were quanti-
tated using stable isotope dilution tandem mass spectrom-
etry. Selectivity and coelution-free quantitation were as-
sured by qualifier ion monitoring.  Results: Method vali-
dation revealed excellent injection repeatability of 1.0% 
coefficient of variation (CV), intraday precision of 1.2% CV 
and interday precision of 2.4% CV. Accuracy determined 
from standard addition experiments was 106.1  8 3.8%. The 
linear calibration range was adapted to physiological creati-
nine concentrations. Comparison of quantitation results 
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 Creatinine is a break-down product of creatine phos-
phate, produced primarily in muscle, released into blood 
and excreted in urine  [6, 7] . Creatinine is released from 
muscle into the blood stream at a highly constant rate 
which is proportional to the muscle mass of the individ-
ual  [7–9] . The kidneys readily excrete creatinine by glo-
merular filtration and proximal tubular secretion with-
out relevant tubular reabsorption  [9, 10] . To account for 
highly variable dilution of spot urine samples, concentra-
tions of urinary excreted compounds are often reported 
after normalization to creatinine concentration  [3–5] .
 Colorimetric determinations of the picrate salt or as-
says based on enzymatic reactions are commonly used in 
clinical chemistry  [11–13] . Creatinine assays examining 
the reaction of creatinine and picric acid were first re-
ported by Jaffé  [14] . To address well-known selectivity 
problems of the Jaffé method, many modifications have 
been proposed, but none of them has eliminated all inter-
ferences  [15, 16] . Various endogenous and exogenous sub-
stances reacting with alkaline picrate are partly contrib-
uting to measured creatinine concentration as ‘noncre-
atinine chromogens’  [10, 15] .
 Additional methods, applying extensive matrix prese-
paration, have been proposed for the determination of 
creatinine in urine, for instance capillary electrophoresis 
 [9, 17] , gas chromatography  [7] , liquid chromatography 
combined with UV  [18] and recently liquid chromatogra-
phy coupled to mass spectrometry  [5, 19, 20] . 
 Flow injection tandem mass spectrometry (FIA-MS/
MS) was introduced more than 2 decades ago for detec-
tion of metabolite profiles indicative of inherited meta-
bolic disease from dried blood spots  [21, 22] . Similar 
methods are now used in many nationwide neonatal 
screening programs  [23, 24] . In the fields of pesticide de-
termination  [25–27] , therapeutic drug monitoring  [28] 
and analysis of adulterated dietary supplements  [29] , 
FIA-MS/MS has recently been presented as an adequate 
alternative to LC-MS/MS. For FIA-MS/MS the mass 
spectrometer is directly coupled to a pump delivering a 
continuous flow of eluent solvents, whereas the LC col-
umn compartment is bypassed. Injection of samples into 
the solvent flow (usually using an autosampler device) 
results in well-formed injection peaks. FIA-MS/MS in 
complex biological matrices like plasma or urine is typi-
cally done after straightforward sample dilution in or-
ganic solvents for precipitation of proteins and reduction 
of ion suppression effects, an approach known as ‘dilute 
and shoot’. The two most important analytical challeng-
es of FIA-MS/MS are: (1) assessment and exclusion of 
coelution bias, which is here addressed by qualifier ion 
monitoring  [29, 30] , and (2) correct quantification in the 
presence of significant ion suppression, which is best 
achieved by using properly matched stable isotope-la-
beled internal standards (SIL-IS)  [31] . If properly applied, 
FIA-MS/MS provides high precision, short run times and 
remarkable cost savings due to elimination of time-con-
suming and possibly error-prone procedures of sample 
cleanup and pre-separation  [27] .
 The aim of our study was to develop a rapid and cost-
effective FIA-MS/MS method for the determination of 
creatinine in human urine. The method was used in com-
bination with LC-MS/MS determination of endogenous 
urinary metabolites in a large-scale clinical intervention 
trial [Niesser et al., unpublished]. The highly precise and 
time-efficient FIA-MS/MS quantitation of creatinine 
from the same urine sample enabled estimation of me-
tabolite excretion from its ratio to creatinine.
 Material and Methods 
 Chemicals, Reagents and Reference Standards 
 Creatinine was purchased from Sigma-Aldrich Chemistry 
(Taufkirchen, Germany) and D 3 -creatinine (creatinine-N-meth-
yl-D 3 ), which was used as internal standard (IS), from CDN Iso-
topes (Dr. Ehrenstorfer GmbH, Augsburg, Germany). HPLC-
grade water and formic acid were purchased from Sigma-Aldrich 
Chemistry. Formic acid in acetonitrile (0.1%, LC-MS grade) was 
ordered from J.T. Baker (Avantor Performace Materials B.V., De-
venter, The Netherlands). Synthetic urine was supplied by Ceril-
liant Corporation (Round Rock, Tex., USA).
 Creatinine and D 3 -creatinine stock solutions were prepared in 
a mixture of acetonitrile and water (50: 50), and stored at –20  °  C.
 Sample Preparation 
 Spot and 24-hour urine samples from healthy adult volunteers 
were collected in urine containers (70 ml, Sarstedt AG & Co., 
Nümbrecht, Germany; Urisafe, 3.0 liter polyethylene, VWR, Ger-
many), filtered (VWR, syringe filter 25 mm, 0.2   m nylon mem-
brane), aliquoted into CryoTubes (1.8 ml and 4.5 ml, Nunc, Ther-
mo Fisher Scientific Inc., Langenselbold, Germany) or Urine-
Monovettes (10 ml, Luer, Sarstedt AG & Co.) and stored at –20  °  C. 
All participants had provided informed consent and the study 
protocol had been reviewed by the ethics committee of the Medi-
cal Faculty of the University of Munich. For sample preparation, 
an automated liquid handler (Gilson ASPEC GX-271, Middleton, 
Wisc., USA) was used. Each deep well (Riplate 1.2 ml 96-deepwell, 
Ritter, Schwabmünchen, Germany) was prefilled with 460   l in-
ternal standard (D 3 -creatinine) in acetonitrile, then 40   l of urine 
sample was added. The solution was mixed and incubated at 4  °  C 
for 60 min to complete protein precipitation. After centrifugation 
at 2,300  g for 10 min at 4  °  C (Rotina 38R, Hettich, Tuttlingen, Ger-
many), 20   l of the supernatant were transferred into a second 
deep well plate (96 wells with 1.0 ml each, polypropylene, Agilent, 
Germany) which was prefilled with 380   l acetonitrile per well. 
The plates were sealed, shaken and placed in the autosampler of 
the LC-MS/MS system.
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 Instrumentation 
 A triple quadrupole mass spectrometer (‘API 2000’, Applied-
Biosystems/Sciex, Darmstadt, Germany) equipped with an elec-
trospray ionization source (‘TurboIonSpray’) was used. FIA-MS/
MS was performed using an autosampler and pump of an HPLC 
system (Agilent Technologies, 1100 series HPLC system, Wald-
bronn, Germany). Data were acquired and processed using Ana-
lyst 1.5.1 software (Applied Biosystems/MDS, Toronto, Ont., 
Canada).
 The electrospray source was operated in positive ion mode; 
optimized source parameters were: curtain gas 50 psi, collision 
gas 6 psi, ion spray voltage 5,000 V, temperature 450  °  C, nebulizer 
gas 40 psi, desolvation gas 80 psi. Compound-dependent ion path 
parameters were set to: declustering potential 20 V, focusing po-
tential 370 V, entrance potential 10 V, dwell time 100 ms and in-
terface heater ON. Multiple reaction monitoring (MRM) tran-
sition parameters for the [M+1] + ions of analyte and internal 
 standard, respectively, were optimized in positive ion mode. 
Quantifier and qualifier MRM transitions and ion path parame-
ters for creatinine and D 3 -creatinine are summarized in  table 1 .
 Flow injection analysis was performed with a mixture of ace-
tonitrile and water (50: 50) acidified with 0.1% formic acid at an 
isocratic flow rate of 400   l/min. Total analysis time per sample 
was 0.4 min plus 0.6 min autosampler operation time.
 Validation Procedures 
 In order to ensure selectivity and to exclude coelution bias, 
qualifier ion monitoring was implemented for both analyte and 
internal standard. Two different MRM transitions as alternative 
fragmentation routes were monitored for each precursor ion  [30, 
32] . The qualifier ion ratio (QIR) was calculated as the peak area 
ratio of these two MRM transitions ( table 1 ) using Analyst 1.5.1 
software. Reference QIR values were determined from pure stan-
dard solutions and compared to QIR of more than 270 native 
urine samples.
 For accuracy research, urine samples collected from 5 healthy 
volunteers and one synthetic urine sample were divided into 
twelve aliquots each. Three of these aliquots were used unspiked 
and three were spiked with low (0.75 mmol/l), medium (5 mmol/l) 
or high concentration (12 mmol/l) of creatinine, respectively.
 Injection repeatability was assessed using a series of eight 
urine preparations which were injected four times each. For test-
ing intraday precision, six urine samples were prepared three 
times each in one batch. Interday precision was assessed by re-
peated preparation and analysis of three urine samples in two 
separate batches.
 Pure creatinine standard dilutions in aqueous urea solution 
(255 mmol/l) were used for external calibration of the isotope di-
lution assay (10 points within 0.25–40 mmol/l). The calibration 
function was fitted by linear regression without weighting and the 
coefficient of determination (R 2 ) was calculated. Statistical analy-
ses were performed with Statistica Version 10 (StatSoft GmbH, 
Hamburg, Germany).
 As an external comparison method, creatinine was assessed 
by the Institute of Clinical Chemistry  at the University of Munich 
Medical Center using the kinetic Jaffé method on a Cobas system 
(Roche Diagnostics, Mannheim, Germany), which is routinely 
applied in clinical chemistry.
 Results 
 Selectivity 
 For verification of selectivity, reference QIR values 
were determined from pure standard solutions. For ease 
of comparison, relative QIR was calculated as the ratio of 
observed QIR to its respective reference QIR. QIR values 
calculated for 270 native urine samples were all within 
the range of 96–104% of reference QIR ( fig. 1 ).
 Accuracy 
 Known amounts of creatinine in low, medium and 
high concentration were added in small volumes to one 
synthetic and to five native urine samples. Accuracy was 
determined dividing the calculated concentrations of 
spiked samples by those of nonspiked samples; mean 
 accuracy was 106.1  8 2.08% (synthetic urine: 108.0  8 
2.72%, mean of native urines: 105.8  8 2.09%). Accuracy 
was constant over the entire range of concentrations ex-
Table 1. I nstrument settings: MRM transitions and optimized ion path parameters of analyte and internal stan-
dard for the ABSciex API 2000
Analyte/internal 
standard
Monoisotopic
mass, m/z
Q1, m/z Q3, m/z CEP, V CE, V CXP, V
Creatinine_1 113.1 114.1 44.0 6 30 4
Creatinine_2* 113.1 114.1 86.0 8 61 2
D3-creatinine_1 116.1 117.1 47.0 6 27 4
D3-creatinine_2* 116.1 117.1 89.0 8 33 2
Q ualifier ions are marked with an asterisk (*); precursor ions (Q1) are selected in positive ion mode as [M+1]+; 
Q3 = product ion; CEP = collision cell entrance potential; CE = collision energy; CXP = collision cell exit po-
tential.
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amined and exhibited no difference between native and 
synthetic urine matrix.
 Precision 
 A series of four runs from eight urine samples was an-
alyzed for injection repeatability yielding an average co-
efficient of variation of 1.0% CV (0.7–1.6%). Intraday pre-
cision was evaluated on six urine samples of low, medium 
and high concentrations which were prepared three times 
in one batch; mean intraday precision was 1.2% CV (0.5–
2.8%). Interday precision, determined from three urine 
samples of different concentration (high and low) ana-
lyzed in two batches, was 2.4% CV (1.7–3.4%).
 Linearity 
 The calibration function was fitted by linear regres-
sion without weighting (y = 0.0019 + 0.0001x; R 2 = 0.9988). 
The lowest point of the calibration curve (0.25 mmol/l) 
was defined as the limit of quantitation covering all con-
centrations determined from 270 spot and 24-hour urine 
samples, respectively.
 External Method Comparison 
 Results obtained by the colorimetric assay were cor-
related with those of the FIA-MS/MS method (y = 51.877 
+ 1.1563x; R 2 = 0.9102;  fig. 2 a). Concentration-dependent 
differences between the two assays were examined using 
a Bland-Altman plot ( fig. 2 b). All but 11 of 270 data points 
were lying within the confidence interval ( 8 1.96 SD).
 Discussion 
 Determination of urinary creatinine by LC-MS/MS 
has already been described in the literature  [19, 20] . Park 
et al.  [20] reported creatinine measurement in 24-hour 
urine samples after separation by reverse-phase liquid 
chromatography. Mass spectrometric analysis with and 
without purification on ion-exchange solid phase extrac-
tion (SPE) cartridges was applied by Huskova et al.  [19] . 
In order to minimize analysis time and costs, we applied 
a radically simple approach using only two-step dilution 
of native urine in acetonitrile (1: 250) for protein precipi-
tation and dilution of sample matrix. FIA-MS/MS was 
then performed from the centrifuged supernatants with-
out further preseparation by liquid chromatography or 
SPE. Extensive validation of our new method showed that 
the additional preparation procedures reported by others 
previously  [19, 20] were unnecessary for reliable and ac-
curate quantitation of urinary creatinine as we used FIA-
MS/MS combined with SIL-IS dilution and qualifier ion 
monitoring.
 Handling of Ion Suppression Effects 
 Since creatinine is among the most abundant com-
pounds in human urine, no dedicated sample preprocess-
ing or separation prior to tandem mass spectrometry was 
deemed necessary. Creatinine can still be determined in 
heavily diluted urine samples where other matrix compo-
nents are diluted so much that dedicated separation is not 
needed (‘dilute and shoot’). Two-step isotope dilution in 
acetonitrile (1: 250 in total) resulted both in protein pre-
cipitation and significant dilution of potentially interfer-
ing matrix components  [33] .
 Ion suppression during electrospray ionization is in-
evitable under such conditions (as in most LC-MS/MS 
methods used in practice)  [34] , but dilution with ade-
quately matched SIL-IS quantitatively corrects for these 
effects allowing accurate quantitation in the presence of 
significant ion suppression  [28, 31, 33, 35] . Micová et al. 
 [28] recently published findings that signal intensities in 
flow injection analysis were lower compared to liquid 
chromatography in consequence of ion suppression, but 
no influence on precision and accuracy of the assay was 
detectable due to the use of SIL-IS. D 3 -creatinine, which 
was used here as the SIL-IS, is very close to the ideal in-
ternal standard for creatinine as the mass difference of 3 
Da is large enough to avoid MRM interferences of isoto-
pologues but still small enough to retain nearly identical 
physicochemical properties.
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 Selectivity 
 Apart from ion suppression, LC-MS/MS assays may 
also be biased by coeluting compounds sharing similar 
mass transitions with the analyte of interest. Our ap-
proach of using fast flow injection analysis without chro-
matographic separation warranted special attention to 
possible coelution bias. We applied the concept of quali-
fier ion monitoring for ensuring unbiased quantitation of 
creatinine  [30, 32] . To that end, characteristic finger-
prints of creatinine ( fig. 3 a) and its internal standard D 3 -
creatinine ( fig. 3 b), consisting of two specific MRM frag-
mentation routes each, were monitored in every sample. 
Comparing QIR of native urine samples to those of pure 
standard solutions by calculating relative QIR showed no 
deviation ( fig. 1 ), thus any coelution bias of the new meth-
odology could be excluded. Unbiased quantitation by 
flow injection analysis was also presented by Johnson 
 [35] , who used a concept of comparing two pairs of ana-
lyte-to-IS mass transition ratios for confirmation of non-
susceptibility to interferences. Additionally, QIR could be 
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determined with high precision in standard and urine 
samples with average injection repeatability in native 
urine of 1.0% CV. 
 Accuracy 
 As no standard reference material was available, a 
standard addition procedure was performed for accuracy 
evaluation  [36] . Low, medium and high concentrations of 
creatinine were spiked into synthetic and native urine for 
calculation of accuracy. Mean accuracy of 106% was 
found comparing spiked and nonspiked samples, which 
is comparable to previously published results  [19] . Accu-
racy was constant over the entire concentration range 
and equal between native and synthetic matrix.
 Precision 
 Results of precision research were compliant with 
widely accepted standard recommendations  [36, 37] , 
which demand precision determined at each concentra-
tion level not exceeding 15% CV. Mean interday precision 
lower than 2.4% CV was found for native urines, which is 
below results presented by Huskova et al.  [19] applying 
SPE for sample preparation, and Park et al.  [20] analyzing 
standard solution using LC-MS/MS. Results for mean in-
traday precision (1.2% CV) and injection repeatability 
(1.0% CV) analyzing native urine were even better than 
in previously published work  [19, 20] .
 This FIA-MS/MS assay is based on a ‘dilute and shoot’ 
sample preparation, which is a radically simple protocol, 
but enables, if well optimized and validated, very reliable 
high-throughput mass spectrometric analysis  [38] . In this 
case, the absence of SPE or liquid extraction and the omis-
sion of chromatographic separation does not hinder but in 
effect benefits superior precision of the assay due to elim-
ination of possible sources of error and variability  [26] .
 Linearity 
 Since creatinine-free urine samples were not available, 
we prepared creatinine dilution series in aqueous urea 
solution for external calibration. The dilution procedure 
was optimized to yield linear detector response over the 
whole calibration range from 0.25 to 40 mmol/l ( fig. 4 ), 
covering the full range of physiologically observed cre-
atinine concentrations in human urine  [39, 40] . The low-
est creatinine concentration measured in 270 urine sam-
ples was 0.8 mmol/l, so the lowest point of the calibration 
curve of 0.25 mmol/l was deemed properly selected.
 External Method Comparison 
 As an external comparison method, colorimetric cre-
atinine determination (Jaffé) on a Cobas Roche modular 
analyzer was compared with our FIA-MS/MS method. 
270 urine samples with concentrations ranging from 0.8 
to 34 mmol/l were analyzed with both methods. Results 
obtained by the FIA-MS/MS method were highly corre-
lated with those of the colorimetric assay ( fig.  2 a), al-
though there was a small but consistent bias towards high-
er values determined by the colorimetric method due to 
the well-known lack of selectivity (reaction with ‘noncre-
atinine chromogens’) of the Jaffé method  [15, 16] . Concen-
tration-dependent differences between the two assays 
were examined using a Bland-Altman plot ( fig. 2 b), where 
259 of 270 data points were within the confidence interval. 
Concentrations determined by the Jaffé assay were on av-
erage 1.7 mmol/l higher and exhibited creatinine concen-
tration-dependent increase of positive bias ( fig. 2 b).
 Automation and High Throughput 
 Our straightforward sample preparation protocol ap-
plying only sample dilution, centrifugation and transfer 
of supernatants was easily implemented by automated 
liquid handling. Use of the robotic pipetting device favor-
ably influenced both speed of sample throughput and 
volume handling precision.
 The flow rate was optimized for robust operation at 
400   l/min. This relatively high flow rate was chosen to 
prevent obstruction of the electrospray needle by deposi-
tion of urinary components which had been observed at 
lower flow rates commonly used for flow injection analy-
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sis (20–100   l/min)  [19, 28] . To assess potential carryover, 
serial measurements of more than 130 injections were 
performed with blank samples measured at the begin-
ning and end of each batch. All blanks revealed the same 
low intensity of background signals (signal to noise ratio 
 ! 1). Both creatinine and its deuterated internal standard 
formed a flow injection peak at 0.14 min ( fig. 3 ). Flow in-
jection analysis peak width was still sufficient to record 
16 scan events for each of the quantifier or qualifier MRM 
transitions. After the creatinine signal, the flow was sus-
tained until 0.4 min for thoroughly flushing the system. 
Auto sampler operation time including needle washing 
accounted for additional 0.6 min. The resulting total
assay time of 1 min per sample allowed for very high 
throughput of more than 1,400 samples a day. Despite 
relatively high costs for equipment acquisition, this kind 
of FIA-MS/MS protocol can be very cost-effective for 
high-throughput screening of large numbers of samples. 
In comparison to previously published mass spectrome-
try methods  [19, 20] , this protocol has much lower costs 
per sample since expensive consumables as chromatogra-
phy columns or SPE equipment are not used.
 Conclusions 
 A rapid and simple FIA-MS/MS method for accurate 
quantitation of creatinine in human urine was developed. 
Isotope dilution tandem mass spectrometry with quali-
fier ion monitoring ensured unbiased quantitation and 
qualification of creatinine in every single sample. Preci-
sion and accuracy were in accordance with widely accept-
ed bioanalytical standard recommendations and mostly 
superior to previously published protocols. Comparison 
with results measured by the colorimetric Jaffé assay rou-
tinely applied in clinical chemistry showed high agree-
ment. Being characterized by a wide linear calibration 
range and excellent accuracy, the assay is applicable for 
the full range of creatinine concentrations observed in 
human urine. The method offers the advantages of low 
required sample volume as well as straightforward and 
fast sample preparation. Feasible throughput of more 
than 1,400 injections per day at low costs per sample 
makes it an attractive choice for creatinine determina-
tions in large-scale epidemiological or clinical studies.
 Although introduced more than 20 years ago, the full 
potential of FIA-MS/MS has so far not been fully recog-
nized in analytical and clinical chemistry. Due to the 
omission of chromatographic preseparation, the occur-
rence of possibly interfering coelutions has to be care-
fully assessed and excluded during validation. The con-
cept of qualifier ion monitoring applied here effectively 
ensures proper qualification and unbiased quantification 
in each sample. FIA-MS/MS used with properly matched 
SIL-IS allows for very accurate and precise quantitative 
analysis which is often superior to conventional LC-MS/
MS. Improved scan speed of current mass spectrometers 
enables parallel quantification of dozens of analytes in a 
single run. Added benefit of multianalyte FIA-MS/MS 
determinations is the exceptionally high accuracy of in-
teranalyte ratios within a single run. The only prerequi-
site for such multianalyte methods is to ensure that the 
expected concentration range of all analytes included fits 
into the dynamic range of the mass spectrometry system. 
Taken together, FIA-MS/MS is a very powerful tool for 
accurate quantification of biomolecules in complex ma-
trices, which has the potential to revolutionize many ap-
plications of quantitative bioanalytical mass spectrome-
try including for example determination of pharmaceu-
ticals, toxic chemicals or diagnostic biomarkers.
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